Authors: Jonathan R Kerr [1*], Peter Christian , Andrea Hodgetts , Paul R Langford , Lakshmi D Devanur , Robert Petty , Beverley Burke , Lindsey I Sinclair , Selwyn CM Richards , Jane Montgomery , Clare McDermott , Tim J Harrison , Paul Kellam , David J Nutt  and Stephen T Holgate 
 St George's University of London, United Kingdom
 Imperial College London, United Kingdom
 University of Bristol, United Kingdom
 Dorset CFS Service, Poole Hospital, United Kingdom
 University College London, United Kingdom
 University of Southampton, United Kingdom
[*] To whom correspondence should be addressed. E-mail: email@example.com.
Accepted 31 July 2006
NLM Citation: PMID: 16935968
Various groups have studied the gene expression in peripheral blood of CFS patients and of those studies which have been confirmed using polymerase chain reaction (PCR), it is clear that the most predominant functional theme is that of immunity and defense. However, we do not yet know the precise gene signature and metabolic pathways involved. Currently, this is being addressed using a microarray representing 47,000 human genes and variants, massive parallel signature sequencing (MPSS) and real-time PCR.
It will be important to ensure that once a gene signature has been identified, that it is specific to CFS and does not occur in other diseases and infections. A diagnostic test is being developed using Surface-Enhanced, Laser-Desorption and Ionisation - Time of Flight (SELDI-TOF) mass spectrometry following a pilot study in which putative biomarkers were identified.
And, finally, clinical trials are being planned; novel treatments which we believe are important to trial in CFS patients are interferon-a and one of the anti-tumour necrosis factor-a drugs.
Key Words: Chronic Fatigue Syndrome, Myalgic encephalomyelitis, biomarkers, gene expression, treatment
Copyright © 2006 Co-Cure
Last Revision: September 30, 2006
Please report any problems with this page to the Webmaster.